Pathos AI has raised $237 Million in New Funding

According to filings with the U.S. Securities and Exchange Commission, Pathos AI has raised $237 Million in new Series E funding. The federal securities law requires the notice to be filed by...

Craig Etkin

November 12, 2026 2 Min Read

15 0

According to filings with the U.S. Securities and Exchange Commission, Pathos AI has raised $237 Million in new Series E funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Bristol Myers Squibb

About Pathos AI
Pathos AI is an AI-enabled, clinical-stage biotechnology company focused on building a new development engine for precision oncology. It combines advanced artificial intelligence, biological modeling, and multimodal patient data to make clinical trials smarter, faster, and more precise. The company says it has the largest collection of oncology patient data, including millions of records linking genomics, transcriptomics, imaging, text, and longitudinal clinical outcomes. Its proprietary platform uses thousands of AI agents to analyze this information, simulate trial scenarios, learn from outcomes, and identify patients most likely to respond to specific therapies. Pathos is developing a scalable, repeatable approach to drug development designed to improve success rates, shorten timelines, and reduce investment risk. Alongside its technology platform, the company is advancing clinical programs with real patients and applying expertise from clinical and translational oncology.

To learn more, visit https://www.pathos.com/
Linkedin: https://www.linkedin.com/company/pathos-ai/

Contact:
Iker Huerga, CEO
https://www.linkedin.com/in/ikerhuerga/